David

$BTC Bitcoiner | Analyzing $ZEC

[Dan Held @danheld]

Morgan Stanley's spot Bitcoin ETF is expected to begin trading as early as tomorrow🔥

Why is this so important?
- 16,000 financial advisors can now recommend Bitcoin
- $7.4T in assets
- The first spot Bitcoin ETF issued directly by a major U.S. bank
- Lowest fee at 0.14%

[WSJ Markets @WSJmarkets]

The owner of the S&P 500 index is licensing the world’s most tracked stock index for the launch of a derivative contract that trades around the clock on the crypto exchange Hyperliquid https://t.co/2naz9XWGoK

[Greg Brockman @gdb]

How AI empowered Paul Conyngham to create a custom mRNA vaccine to cure his dog’s cancer when she had only months to live. The first personalized cancer vaccine designed for a dog:

[Justin Bechler @1914ad]

https://t.co/fA1UmGvKou

[Coin Bureau @coinbureau]

🚨BREAKING: Crypto liquidations soar to $9.4 BILLION in 24 hours – the LARGEST single-day event ever.

Bigger than LUNA. Bigger than COVID. Bigger than FTX.

We just witnessed history.

[David @davejliu]

A huge milestone for the crypto industry.

[Brian Armstrong @brian_armstrong]

Coinbase just became the first and only crypto company to join the S&P 500.

This milestone represents what the true believers, from retail investors to institutional investors to our employees and partners, knew all along.

Crypto is here to stay.

[David @davejliu]

@zerohedge Cattle traders: Tariff-fic

[zerohedge @zerohedge]

Goldman chief economist: Fed goes 25

Goldman global head of trading: Fed goes 50

[David @davejliu]

@zerohedge Fundamental vs. Technical

[David @davejliu]

When your connecting flight is delayed until midnight, but you happen to meet a pianist who shares the same passion for Yiruma 🥰💕

[David @davejliu]

@3Things10 haven’t listened to the earnings call. Will update once do 😁

[David @davejliu]

$FLGT Q1 earnings:
• Q1 Revenue $66.2 million (-79% YoY)
• Q1 Core Revenue $62.7 million (+150% YoY)
• Sees Q2 Core Revenue $62 million (+37% YoY)
• Sees FY23 Core Revenue $250 million (+38% YoY)
• Sees FY23 Non-GAAP EPS loss of $1.25 per share

[David @davejliu]

https://t.co/VvFrGXRRmE

[David @davejliu]

Source: https://t.co/tVtqQUxD0y

[David @davejliu]

$FLGT Q4 earnings:
• Q4 Revenue $67.7 million (-73% YoY)
• Q4 Core Revenue $55 million (+97% YoY)
• Sees Q1 Revenue $56 million (-83% YoY)
• Sees FY23 Revenue $240 million (-61% YoY)
• Sees FY23 Non-GAAP EPS loss of $1.25 per share

[David @davejliu]

@LoRezTrader Hope the deal is made to serve shareholders' best interests. Time will tell .

[David @davejliu]

@3Things10 My pleasure! I think Fulgent will prove itself.

[David @davejliu]

Fulgent $FLGT agrees to buy Fulgent Pharma in a cash and stock deal valued at $100 million.

The company will gain access to novel nano-drug delivery platform with US FDA drug master file.

[David @davejliu]

@3Things10 I tend to believe that Ming saw big opportunities in this pharma business.

When I looked at the pipeline of Fulgent pharma, I noticed "STING Agonist." If you remember the article I wrote about the Covid vaccine by Fulgent, it's actually this adjuvant that was used in the trial.

[David @davejliu]

@3Things10 I would say the deal is a potential conflict of interest, but only time will tell if it's made to create shareholder value.

[David @davejliu]

Source: https://t.co/DJurAISLHQ

[David @davejliu]

Fulgent Pharma believes its lead drug candidate, FID-007, has achieved proof-of-concept in preliminary human clinical trials for the treatment of various cancer types, including Head and Neck, Ampullary, Pancreatic, NSCLC, and Breast.